Home › Chronic Inflammatory Demyelinating Polyradiculoneuropathy › Pennsylvania
Chronic Inflammatory Demyelinating Polyradiculoneuropathy clinical trials in Pennsylvania
6 studies for Chronic Inflammatory Demyelinating Polyradiculoneuropathy are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Site Number - 1616, Philadelphia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07032662A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
- Penn Medicine University City, Philadelphia
- Jefferson Health Honickman Center, Philadelphia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07091630A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
- Perelman Center for Advanced Medicine, Philadelphia
- Jefferson Health Honickman Center, Philadelphia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06920004A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Penn State Health Milton South Hershey Medical Center- Site Number : 8400042, Hershey
- Penn Medicine: University of Pennsylvania Health System- Site Number : 8400022, Philadelphia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06290141Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)
- Investigational Site, Swiftwater
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT06968975A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Penn Blood Disorders Program - Hospital of The University of Pennsylvania, Philadelphia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 23, 2026 · NCT06798012From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.